MLICM
CODX

Metropolitan Life Insurance Company (MetLife)’s Co-Diagnostics CODX Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio CODX Stock Details CODX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-238
Closed -$68.2K – 2743
2021
Q1 		$68.2K Sell
238
-45
-16% -$18K ﹤0.01% 2507
2020
Q4 		$78.9K Hold
283
– – ﹤0.01% 2432
2020
Q3 		$115K Hold
283
– – ﹤0.01% 2140
2020
Q2 		$164K Buy
+283
New +$129K ﹤0.01% 1936

Other funds holding CODX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PPA
Parametric Portfolio Associates Seattle, Washington $190B AUM 18.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
ARC
Advisor Resource Council Dallas, Texas $355M AUM 30.05% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s CODX Position: Q2 2021 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Co-Diagnostics (CODX) in Q2 2021, closing a stake of 238 shares — an estimated $68.2K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in CODX in Q2 2020 and held it in 4 quarters. The position peaked at $164K in Q2 2020. 88 funds tracked by Wall St. Rank hold CODX as of Q2 2021.

  • Metropolitan Life Insurance Company (MetLife) reported no remaining Co-Diagnostics position as of Q2 2021 after selling out during the quarter.
  • Metropolitan Life Insurance Company (MetLife) sold 238 Co-Diagnostics shares in Q2 2021, an estimated $68.2K.
  • Metropolitan Life Insurance Company (MetLife) first reported a position in Co-Diagnostics in Q2 2020 and held it in 4 quarters.
  • Metropolitan Life Insurance Company (MetLife)'s Co-Diagnostics position peaked at $164K in Q2 2020.
  • 88 funds tracked by Wall St. Rank held Co-Diagnostics as of Q2 2021.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q2 2021, filed 16 Aug 2021.